These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 16898935)

  • 1. Complete remission of a case of classical Kaposi's sarcoma with liposomal doxorubicin and radiotherapy.
    Ezquerra GM; Redonnet MS; Cuchillero RO; Millet PU
    J Eur Acad Dermatol Venereol; 2006 Aug; 20(7):901-2. PubMed ID: 16898935
    [No Abstract]   [Full Text] [Related]  

  • 2. Liposomal doxorubicin: new preparation. Useful in Kaposi's sarcoma.
    Prescrire Int; 1998 Jun; 7(35):69-70. PubMed ID: 10342919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma.
    Amantea MA; Forrest A; Northfelt DW; Mamelok R
    Clin Pharmacol Ther; 1997 Mar; 61(3):301-11. PubMed ID: 9084455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin.
    Gottlieb JJ; Washenik K; Chachoua A; Friedman-Kien A
    Lancet; 1997 Nov; 350(9088):1363-4. PubMed ID: 9365453
    [No Abstract]   [Full Text] [Related]  

  • 5. Gastrointestinal and cutaneous AIDS-related Kaposi's sarcoma: different activity of liposomal doxorubicin according to location of lesions.
    Hernández-Morales DE; Hernández-Zaccaro AE
    Eur J Cancer Care (Engl); 2005 Jul; 14(3):264-6. PubMed ID: 15952971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.
    Coukell AJ; Spencer CM
    Drugs; 1997 Mar; 53(3):520-38. PubMed ID: 9074848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal daunorubicin: new preparation. Kaposi's sarcoma: occasional remission.
    Prescrire Int; 1998 Apr; 7(34):41-2. PubMed ID: 10183380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penile ulceration during pegylated doxorubicin chemotherapy of classical Kaposi's sarcoma.
    Cannavò SP; Borgia F; Scimone A; Guarneri B
    Acta Derm Venereol; 2009; 89(2):216-7. PubMed ID: 19326025
    [No Abstract]   [Full Text] [Related]  

  • 9. Paclitaxel for treating KS.
    Proj Inf Perspect; 1997 Nov; (23):15. PubMed ID: 11365372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Successful treatment with liposomal doxorubicin and foscarnet in a patient with widespread Kaposi's sarcoma and human herpes virus 8-related, serious hemophagocytic syndrome, after renal transplantation].
    Bossini N; Sandrini S; Setti G; Luppi M; Maiorca P; Maffei C; Cancarini G
    G Ital Nefrol; 2005; 22(3):281-6. PubMed ID: 16001371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin.
    Castiñeiras I; Almagro M; Rodríguez-Lozano J; Fernández-Jorge B; Paradela S; Pozo JD; Fonseca E
    J Dermatolog Treat; 2006; 17(6):377-80. PubMed ID: 17853313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Kaposi's sarcoma.
    Gascón P; Schwartz RA
    Dermatol Clin; 1994 Apr; 12(2):451-6. PubMed ID: 8045056
    [No Abstract]   [Full Text] [Related]  

  • 13. Kaposi's sarcoma: DaunoXome approved.
    AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low to moderate cumulative doses of pegylated liposomal doxorubicin in the treatment of classic Kaposi sarcoma in elderly patients with comorbidities.
    Potouridou I; Korfitis C; Ioannidou D; Polydorou D; Zakopoulou N; Stratigos AJ; Katsambas AD
    Br J Dermatol; 2008 Feb; 158(2):431-2. PubMed ID: 18067475
    [No Abstract]   [Full Text] [Related]  

  • 15. Timing of highly active antiretroviral therapy and chemotherapy for Kaposi's sarcoma in patients with HIV infection.
    Loke WC; Spittle MF; Mitchell S; Kulasegaram R
    Int J STD AIDS; 2006 Aug; 17(8):565-6. PubMed ID: 16925908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA approves KS drug. Food and Drug Administration. Florida Department of Health and Rehabilitation Services.
    AIDS Alert; 1996 Jan; 11(1):11-2. PubMed ID: 11363227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma.
    White RM
    AIDS; 1997 Sep; 11(11):1412-3. PubMed ID: 9302461
    [No Abstract]   [Full Text] [Related]  

  • 18. [Current therapeutic strategies in AIDS-associated Kaposi sarcoma. An overview including results of a personal study].
    Mauss S; Szelényi H; Jablonowski H
    Med Klin (Munich); 1994 Oct; 89(10):550-5. PubMed ID: 7808356
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma.
    Hjortsberg C; Persson U; Lidbrink E; Bennett C
    Acta Oncol; 1999; 38(8):1063-7. PubMed ID: 10665764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Kaposi's sarcoma.
    Tur E; Brenner S
    Arch Dermatol; 1996 Mar; 132(3):327-31. PubMed ID: 8607639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.